Finally, incentives must be found to encourage pharmaceutical companies to develop drugs that fulfill the needs of patients still awaiting therapy. There are more than 6,000 rare and neglected diseases – many in developing countries – that lack remedies.
最后，我们必须寻求一些激励机制来鼓励制药公司开发满足亟待治疗的病人需求的新药。还有6000多种罕见和被忽视的疾病—许多都产生在发展中国家—缺少对症药物。我们所面临的挑战是如何来生产那些经济回报非常有限（因为病人太少或太穷）的新药。